(Q33653596)

28 July 2017

1 reference

title

Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma (English)

1 reference

28 July 2017

1 reference

J Kim

1

1 reference

28 July 2017

C J Logothetis

series ordinal

2

1 reference

28 July 2017

publication date

1 May 1999

1 reference

Urologic Clinics of North America

28 July 2017

published in

1 reference

28 July 2017

volume

26

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

281-290

1 reference

The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker"

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Antiproliferative effects of suramin on androgen responsive tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Inhibition by suramin of mitochondrial ATP synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

The endocrine component of prostatic carcinomas, mixed adenocarcinoma-carcinoid tumours and non-tumour prostate. Histochemical and ultrastructural identification of the endocrine cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Adaptive control with feedback strategies for suramin dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Neuroendocrine differentiation in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Critical assessment of prostate cancer staging

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin binds to platelet-derived growth factor and inhibits its biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Antiandrogen withdrawal syndrome with nilutamide

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Argentaffin and argyrophil cells in the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Effect of Suramin on Human Prostate Cancer Cells in Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin-induced polyneuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin antiviral therapy in the acquired immunodeficiency syndrome. Clinical, immunological, and virologic results

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

The McGill Pain Questionnaire: Major properties and scoring methods

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Bone scanning and plasma phosphatases in carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Treatment of Metastatic Endocrine-Unresponsive Carcinoma of the Prostate Gland With Multiagent Chemotherapy: indicators of Response to Therapy2

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Taxol: a novel investigational antimicrotubule agent

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Chemotherapy Programs of the National Prostatic Cancer Project (NPCP)

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

The development of a method for assessing the quality of life of cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Acid phosphatase: defining a role in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Essai de traitement de la maladie du sommeil, au Cameroun, par le Bayer 205

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Interleukin-6: a candidate mediator of human prostate cancer morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0094-0143%2805%2970068-9

7 January 2021

10.1016/S0094-0143(05)70068-9

Identifiers

DOI

1 reference

28 July 2017

1 reference